Belantamab Mafodotin (BLENREP®) is an antibody-drug conjugate (ADC) with anti-BCMA antibody that binds to BCMA on tumor cell surfaces causing cell cycle arrest and inducing antibody-dependent cellular cytotoxicity (ADCC). Belantamab Mafodotin is currently FDA approved for use in multiple myeloma patients who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. It is investigational in all other uses. Patients can click here to locate providers of Belantamab Mafodotin (BLENREP®).
On November 22, 2022, GSK announced that it has initiated the process for withdrawal of the US marketing authorization for Blenrep following the request of the US Food and Drug Administration (FDA). This request was based on the previously announced outcome of the DREAMM-3 phase III confirmatory trial, which did not meet the requirements of the US FDA Accelerated Approval regulations. Learn More
SparkCures ID | 130 |
---|---|
Developed By | GlaxoSmithKline |
Brand Name | Blenrep® |
Generic Name | Belantamab Mafodotin |
Additional Names | GSK2857916 |
Treatment Classifications | |
Treatment Targets |
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
The following is a listing of clinical trials for patients with Smoldering Myeloma.
June 01, 2020
Patients can locate providers of Belantamab Mafodotin (BLENREP®) based on location/zip code.
GSK recognises that there may be circumstances when it is appropriate for Healthcare Professionals to give their patients Investigational medicines to treat life threatening or seriously debilitating diseases/conditions where no satisfactory alternatives exist.
SparkCures is working closely with GlaxoSmithKline to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.
Learn more about how we work with industry partners